Regeneron prevails over amgen in antitrust pcsk9 lawsuit protecting biotech innovation and patient access to life-saving treatments

Federal court jury found amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent praluent ® (alirocumab) from competing in the market

REGN Ratings Summary

REGN Quant Ranking